HC Wainwright Has Positive Forecast for NMRA Q2 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Neumora Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.30) for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.29) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($1.10) EPS, FY2029 earnings at ($0.26) EPS and FY2030 earnings at $1.51 EPS.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Monday, March 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

NMRA has been the topic of a number of other reports. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Mizuho set a $6.00 price objective on shares of Neumora Therapeutics in a research report on Monday, January 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Neumora Therapeutics in a report on Tuesday. Leerink Partners assumed coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.67.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock opened at $2.09 on Thursday. The business has a 50-day simple moving average of $2.74 and a 200 day simple moving average of $2.32. Neumora Therapeutics has a 52 week low of $0.61 and a 52 week high of $3.65. The stock has a market cap of $380.46 million, a price-to-earnings ratio of -1.44 and a beta of 3.08. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15.

Institutional Trading of Neumora Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of NMRA. Legacy Private Trust Co. purchased a new stake in shares of Neumora Therapeutics in the third quarter valued at $25,000. Hsbc Holdings PLC purchased a new stake in Neumora Therapeutics in the 4th quarter worth about $27,000. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics during the third quarter valued at approximately $31,000. Fred Alger Management LLC bought a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $40,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Neumora Therapeutics during the second quarter valued at approximately $41,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Insider Buying and Selling at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the sale, the insider owned 7,395,185 shares in the company, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 23,387 shares of company stock valued at $82,647 over the last ninety days. Company insiders own 26.80% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.